The concept of RNA as a medicine is not new. The act of using ribonucleic acid molecules to treat or prevent diseases by affecting biological pathways has been pursued for almost 50 years. Antisense oligonucleotides were first synthesized in the 1970s; aptamers first described in the 1990s; the first use of exogenous mRNA to induce […]

Bolt Biotherapeutics (NASDAQ:BOLT) is developing tumor-targeting therapies that leverage the power of basic components of the innate and adaptive immune systems to attack the tumor microenvironment. “We’ve demonstrated preclinically that this approach allows us to train the immune system to recognize and destroy a tumor, as well as leave a subject with an immunologic memory of […]

DTx Pharma is a therapeutics company focused on solving one of the biggest challenges limiting the expansion of genetic medicines as a therapeutic class: the delivery of RNA therapeutics beyond the liver. To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, […]